Hormonal Contraceptives - New directions in a competitive market

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-11-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG's Yasmin and Organon's NuvaRing which fulfill key strategies: additional indications and alternative delivery modes. Market growth is not expected to falter if companies employ these lifecycle strategies which promote uptake in a competitive market.


Scope

  • Identification of the key products and players in the seven major markets and their strategies for success
  • Benchmarking lifestyle management strategies for hormonal contraceptives
  • Assessment of the potential of the switch from prescription to over-the-counter opportunity
  • Examination of the pipeline and future directions of the market, such as the elusive but potentially lucrative male hormonal contraception opportunity


    • Report Highlights
    Despite the slow growth of the Japanese market, opinion leaders believe it can be enlivened by the introduction of innovative delivery methods and by following the sales and marketing strategies successfully employed by Wyeth in Japan.

    Should hormonal contraceptives become available over the counter, several companies are suitably placed to enter the new market, including those with two strong brands and those facing patent expiry on a key portfolio product.

    Additional indications provide a key growth opportunity. The acne market is saturated with contraceptives and the Yasmin family is synonymous with premenstrual symptoms. However, estrogen deficiency and uterine fibroid indications are commercially attractive.


    Reasons to Purchase

  • Understand key opinion leaders views on topical issues in the hormonal contraceptive market
  • Explore the avenues open to a company intending to optimize brand sales in a mature and competitive market
  • Determine the strengths of and challenges to products with innovative delivery mechanisms, dosing regimens, and additional indications

    • Table of Contents

    Other users found this report page using the following search terms: contraception contraceptive market contraceptive hormonal contraceptives contraception oral analysis nuvaring brands brand

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.